aap focus on implantable biomaterials

aap Implantate AG, a medical technology company listed in the Prime Standard Segment on the Frankfurt Stock Exchange and specialized in biomaterials and implants for trauma and joint reconstruction, will in the future focus solely on implantable medical biomaterials.

After acquiring the Dutch biomaterials specialist Fame Medical Group, aap will in 2007 earn more than 70 percent of planned consolidated sales totaling around EUR 30 million in this segment.

In the months ahead various strategic options will be investigated for the Trauma/Joint Reconstruction division, located in Berlin. Initially, subject to approval by the annual meeting of shareholders planned for August 27, 2007, this unit with around 90 employees is to be transferred to a separate subsidiary. For 2007 aap plans double-digit sales growth in this segment.

For aap, focusing on implantable biomaterials in the core areas bone cements, bone replacement materials, infection therapy and tissue generation means concentrating on fast-growing and profitable niche markets. In these markets aap is already a worldwide technology leader and has in recent years built up development and sales partnerships with world-leading orthopedic, spinal column and dental enterprises.

To visualize the realignment aap plans to rename the parent company aap BioImplants AG.